Information Provided By:
Fly News Breaks for September 20, 2017
EPZM
Sep 20, 2017 | 04:56 EDT
Jefferies analyst Carmen Augustine started Epizyme with a Buy rating and $23 price target. The company, with potential to have a drug on market as soon as 2019, has a a "catalyst-rich" next 12 months, the analyst contends. Augustine believes data are encouraging for tazemetostat in larger blood cancer indications.
News For EPZM From the Last 2 Days
There are no results for your query EPZM